Explore this guide to understand lenacapavir and its role in modern HIV treatment. Learn how this long acting capsid inhibitor works, why it is used with other antiretroviral medicines, and how its dosing schedule differs from daily HIV medicines. Read insights about eligibility, treatment monitoring, resistance considerations, possible side effects, and the importance of following scheduled injections.
Lenacapavir is an antiretroviral medicine belonging to the capsid inhibitor class. For HIV treatment, it is marketed as Sunlenca and is approved for certain adults with heavily treatment experienced, multidrug resistant HIV who are experiencing virologic failure. It is used together with other antiretroviral medicines rather than as a standalone treatment.
Lenacapavir works by targeting the HIV capsid, a protein structure involved in several stages of the viral life cycle. Because it acts at a different target from many traditional antiretroviral medicines, it can provide an additional treatment option for people whose HIV has developed resistance to multiple drug classes.
For treatment, lenacapavir begins with an initiation phase involving oral tablets and injections administered by a healthcare professional. After initiation, the treatment schedule includes two subcutaneous injections every six months. Keeping scheduled appointments is important because maintaining appropriate drug levels helps support continued viral suppression and reduces concerns about resistance.
Key points to learn include:
Understanding lenacapavir also involves recognizing the importance of medical supervision. Healthcare professionals may review a person's treatment history, HIV viral load, resistance information, other medicines, and potential drug interactions when determining whether lenacapavir is appropriate.
Possible adverse effects and safety considerations should also be discussed with a healthcare professional. Injection-site reactions can occur, while other reactions may include nausea or headache. People receiving HIV treatment should not change, delay, or stop their medication without professional guidance.
Important considerations to read and understand include:
Lenacapavir is also used under the brand name Yeztugo for HIV pre-exposure prophylaxis, or PrEP, which is a different use from HIV treatment. Yeztugo is intended for HIV-negative people at risk of acquiring HIV and requires HIV testing before initiation and before subsequent injections. Therefore, lenacapavir for treatment and lenacapavir for prevention should not be confused.
This guide provides general educational information about lenacapavir and HIV treatment. It does not replace individualized medical advice, diagnosis, or treatment planning. Anyone considering or currently receiving HIV treatment should work with a qualified healthcare professional.